multi-strain probiotic capsule  (Protexin Inc)

Journal: International Journal of General Medicine

Article Title: Effects of Probiotics on Neurodegenerative Disease-Related Symptoms and Systemic Inflammation: A Systematic Review

doi: 10.2147/IJGM.S499406

Figure Lengend Snippet: Detailed Characteristics of Included Studies in the Systematic Review

Article Snippet: Rahimlou M, 2022b , Iran , MS , 32/33 , 39.9(8.76)/42.15(11.98) , 6/26, 12/21 , 2 multi-strain probiotic capsules: Each probiotic capsule (Protexin) contained minimum 2 billion live microorganisms (2 × 10 9 CFU/capsule), equivalent to 10 billion live microorganisms per gram (1 × 10 10 CFU/gram) of 14 strains (Bacillus subtilis PXN 21, Bifidobacterium bifidum PXN 23, Bifidobacterium breve PXN 25, Bifidobacterium infantis PXN 27, Bifidobacterium longum PXN 30, Lactobacillus acidophilus PXN 35, Lactobacillus delbrueckii ssp. bulgaricus PXN 39, Lactobacillus casei PXN 37, Lactobacillus plantarum PXN 47, Lactobacillus rhamnosus PXN 54, Lactobacillus helveticus PXN 45, Lactobacillus salivarius PXN 57, Lactococcus lactis ssp. lactis PXN 63, Streptococcus thermophilus PXN 66), cellulose (bulking agent) and vegetable capsule (Hydroxypropylmethyl Cellulose) /Qd , Two placebo capsules(maltodextrin) /Qd , 12w , CRP, IFN-γ, IL-17, IL-35, TNF-α, TGF-β, FOXP3 , None.

Techniques: Comparison, Probiotics, Bacteria, Capsules, Maltodextrin, Activity Assay, Starch

Journal: International Journal of General Medicine

Article Title: Effects of Probiotics on Neurodegenerative Disease-Related Symptoms and Systemic Inflammation: A Systematic Review

doi: 10.2147/IJGM.S499406

Figure Lengend Snippet: Detailed Characteristics of Included Studies in the Systematic Review

Article Snippet: Rahimlou M, 2022b , Iran , MS , 32/33 , 39.9(8.76)/42.15(11.98) , 6/26, 12/21 , 2 multi-strain probiotic capsules: Each probiotic capsule (Protexin) contained minimum 2 billion live microorganisms (2 × 10 9 CFU/capsule), equivalent to 10 billion live microorganisms per gram (1 × 10 10 CFU/gram) of 14 strains (Bacillus subtilis PXN 21, Bifidobacterium bifidum PXN 23, Bifidobacterium breve PXN 25, Bifidobacterium infantis PXN 27, Bifidobacterium longum PXN 30, Lactobacillus acidophilus PXN 35, Lactobacillus delbrueckii ssp. bulgaricus PXN 39, Lactobacillus casei PXN 37, Lactobacillus plantarum PXN 47, Lactobacillus rhamnosus PXN 54, Lactobacillus helveticus PXN 45, Lactobacillus salivarius PXN 57, Lactococcus lactis ssp. lactis PXN 63, Streptococcus thermophilus PXN 66), cellulose (bulking agent) and vegetable capsule (Hydroxypropylmethyl Cellulose) /Qd , Two placebo capsules(maltodextrin) /Qd , 12w , CRP, IFN-γ, IL-17, IL-35, TNF-α, TGF-β, FOXP3 , None.

Techniques: Comparison, Probiotics, Bacteria, Capsules, Maltodextrin, Activity Assay, Starch

Journal: Journal of Neurogastroenterology and Motility

Article Title: Total Transit Time and Probiotic Persistence in Healthy Adults: A Pilot Study

doi: 10.5056/jnm22031

Figure Lengend Snippet: Schematic representation of the study design. Schematics of the 10-week study, including a 4-week baseline washout period (Day −28 to 0), followed by a 2-week intervention (daily multi-strain probiotic intake, Day 0 to 14), and a 4-week washout (Day 14 to 42). Daily diary and weekly questionnaire (Day −7 onwards) are represented by the green line, days of transit markers intake (Day 0 to 2) are marked by grey squares, and stool sample collection time points (Day −3 onwards) are identified by black squares. GSRS, Gastrointestinal Symptom Rating Scale.

Article Snippet: The commercial multi-strain probiotic (30 billion CFU/capsule) manufactured by Lallemand Health Solutions Inc, was composed of Lactobacillus helveticus R0052 (45%), Lacticaseibacillus paracasei HA-108 (17%), Bifidobacterium breve HA-129 (16%), Bifidobacterium longum R0175 (6%), and Streptococcus thermophilus HA-110 (16%).

Techniques:

Journal: Journal of Neurogastroenterology and Motility

Article Title: Total Transit Time and Probiotic Persistence in Healthy Adults: A Pilot Study

doi: 10.5056/jnm22031

Figure Lengend Snippet: Strain-specific Primers Used for the Detection of Probiotic Strains

Article Snippet: The commercial multi-strain probiotic (30 billion CFU/capsule) manufactured by Lallemand Health Solutions Inc, was composed of Lactobacillus helveticus R0052 (45%), Lacticaseibacillus paracasei HA-108 (17%), Bifidobacterium breve HA-129 (16%), Bifidobacterium longum R0175 (6%), and Streptococcus thermophilus HA-110 (16%).

Techniques: Sequencing, Amplification

Journal: Journal of Neurogastroenterology and Motility

Article Title: Total Transit Time and Probiotic Persistence in Healthy Adults: A Pilot Study

doi: 10.5056/jnm22031

Figure Lengend Snippet: Persistence of probiotic strains according to whole gut transit time (WGTT) subgroups. (A) Kinetics of the average onset and recovery of Lactobacillus helveticus R0052, Bifidobacterium longum R0175, Lacticaseibacillus paracasei HA-108, and Bifidobacterium breve HA-129 strains (from top, respectively) over the study duration in the 3 transit time categories (Fast, Intermediate [Inter.], and Slow). Mixed model ANOVA with Tukey’s multiple comparison test. * P < 0.05. (B) Time to detection (onset), (C) time to non-detection (persistence), and (D) duration of detection (bottom) in days for individual participants in each transit category for L. helveticus R0052, B. longum R0175, L. paracasei HA-108, and B. breve HA-129 strains (left to right). Ordinary one-way ANOVA with Tukey’s multiple comparisons test. * P < 0.05.

Article Snippet: The commercial multi-strain probiotic (30 billion CFU/capsule) manufactured by Lallemand Health Solutions Inc, was composed of Lactobacillus helveticus R0052 (45%), Lacticaseibacillus paracasei HA-108 (17%), Bifidobacterium breve HA-129 (16%), Bifidobacterium longum R0175 (6%), and Streptococcus thermophilus HA-110 (16%).

Techniques: Comparison

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: Quantity of samples collected during the PICO study.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques:

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: The Shannon diversity index, which is a heterogeneity measure that combines richness and evenness components of microbial diversity does not significantly differ when subjects take probiotics.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques: Probiotics

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: (A) Subjects in the probiotic group had a significantly lower abundance of the bacterial family Verrucomicrobiaceae at week 8 than placebo treated subjects; (B) Members of the bacterial genus Bacteroides were significantly reduced in abundance between weeks 0 to 4 in probiotic treated subjects; (C) Ruminococcus (family Lachnospiraceae) tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group; * 0.05 < p < 0.1 and ** p ≤ 0.05.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques: